Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 20/20 | 0.53 |
| ▸ | CA2 | P00918 | 20/20 | 0.53 |
| ▸ | CA9 | Q16790 | 20/20 | 0.53 |
| ▸ | CA7 | P43166 | 15/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 15/20 | 0.53 |
| ▸ | CA12 | O43570 | 15/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765068 | 0.75 | MMP13 (0.45) | CA1CA2CA9CA7CA14 | |
| SCHEMBL5697123 | 0.72 | MMP13 (0.42) | CA1CA2CA9CA7CA14 | |
| SCHEMBL6761897 | 0.71 | ACACB (0.44) | — | |
| SCHEMBL16053390 | 0.65 | CA1 (0.70) | CA1CA2CA9CA7CA14 | |
| SCHEMBL21768167 | 0.65 | MAOB (0.56) | CA1CA2CA9CA7CA14 | |
| SCHEMBL30089453 | 0.65 | MAOB (0.56) | CA1CA2CA9CA7CA14 | |
| SCHEMBL14493373 | 0.64 | CA12 (0.87) | CA1CA2CA9CA7CA14 | |
| SCHEMBL6705933 | 0.63 | POLB (0.39) | — | |
| SCHEMBL23628467 | 0.62 | CA1 (0.63) | CA1CA2CA9CA7CA14 | |
| SCHEMBL14157570 | 0.62 | CA1 (0.50) | CA1CA2CA9CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | CA1 724/4885CA2 300/4885CA9 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.